Brought to you by

Qiagen offers to buy Cellestis for $355mm, later ups offer
30 Aug 2011
Executive Summary
Molecular diagnostics company Qiagen NV is proposing to buy public Australian diagnostics firm Cellestis Ltd. for A$341mm ($355mm) in cash, or $3.69 per share (a 25% premium).
Deal Industry
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com